Correction to: Infect Dis Ther (2023) 12:2725–2743 10.1007/s40121-023-00891-1
In Table 2, one of the subheaders was missed in the original article. The corrected Table 2 is given below. Original article has been corrected.
Table 2.
SARS-CoV-2 antibodies at baseline, by treatment arm in the modified intention-to-treat population
| Molnupiravir | Placebo | Total | ||||
|---|---|---|---|---|---|---|
| Participants in population | N = 709 | N = 699 | N = 1408 | |||
| Nucleocapsid antibodies | ||||||
| Positive, n (%) | 139 | (19.6) | 151 | (21.6) | 290 | (20.6) |
| Negative, n (%) | 557 | (78.6) | 535 | (76.5) | 1092 | (77.6) |
| Unknowna, n (%) | 13 | (1.8) | 13 | (1.9) | 26 | (1.8) |
| Neutralizing anti-spike antibodies | ||||||
| Positive, n (%) | 190 | (26.8) | 188 | (26.9) | 378 | (26.8) |
| Negative, n (%) | 513 | (72.4) | 506 | (72.4) | 1019 | (72.4) |
| Unknowna, n (%) | 6 | (0.8) | 5 | (0.7) | 11 | (0.8) |
N total number of participants, n number of participants with the corresponding characteristic
aMissing data, invalid sample, tests not done, or results reported as “unknown” are categorized as unknown
Footnotes
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.